



University of Silesia, Katowice, Poland
11 – 22 March 2013

Ligand-receptor interactions



Dr. Pavel Polishchuk

A.V. Bogatsky Physico-Chemical Institute
of National Academy of Sciences of Ukraine
Odessa, Ukraine

pavel_polishchuk@ukr.net

Interactions

2



Receptors and ligands

“Receptive substance”



Langley, 1878

“Receptor”,
“Pharmacophore”



Paul Ehrlich, 1900

Lock-and-key paradigm³




Emil Fisher, 1894

Lock-and-key paradigm



Ligand-receptor interaction

4



$$K = \frac{[RL]}{[R][L]}$$

$$\Delta G^\circ = -RT \ln K = -2.303RT \log K$$

$$\Delta G^\circ = 1.42 \log K \quad \text{at } 37^\circ\text{C}$$


Protein Data Bank (PDB)

5



<http://www.pdb.org/pdb/home/home.do>

Exp.Method	Proteins	Nucleic Acids	Protein/NA Complexes	Other	Total
X-RAY	72761	1440	3746	2	77949
NMR	8615	1022	192	7	9836
ELECTRON MICROSCOPY	342	41	123	0	506
HYBRID	46	3	2	1	52
other	147	4	5	13	169
Total	81911	2510	4068	23	88512



Enthalpy and entropy


$$\Delta G = \Delta H - T\Delta S$$

Entropy-enthalpy compensation


7

In short, the tighter and more directed an interaction, the less entropically favorable it is.


Bonding opposes motion, and motion opposes bonding.



β -adrenoreceptor ligands




adenosine A1 receptor ligands




Cooperativity

Thrombin inhibitors

10




$$\text{Cooperativity} = 18.0 - (5.1 + 8.6) = 4.3 \text{ kJ/mol}$$




PDB: 2J4I

Factor Xa inhibitors




$K_i = 1 \text{ nM}$



$K_i = 39 \text{ } \mu\text{M}$

Structural water

12







Entropy gain up to 2 kJ/mol

Structural water

Inhibitors of Epidermal Growth Factor Receptor (EGFR) Kinase




13




Structural water

Inhibitors of acetylcholinesterase (AChE)

14




Huperzine





Catechol Analogue

Overlay of 15 PDE10 inhibitors



Specific interactions. Hydrogen bonding.

16




hydrogen
bond
donor

hydrogen
bond
acceptor

hydrogen
bond
acceptor

hydrogen
bond
donor






Distance preference



Hydrogen bonding.

17

Angle preference




1. Donor – hydrogen •• acceptor
 $> 150^\circ$
2. C=O •• H
 120°
Exception: sulfonyl
3. Carboxyl groups
syn orientation is preferred
4. Aromatic acceptors
deviation from the plane $< 30^\circ$


Hydrogen bonding.

18


Major urinary protein



$$K_d = 1011 \mu\text{M}$$




$$K_d = 0.63 \mu\text{M}$$



$$K_d = 0.18 \mu\text{M}$$

Basicity \longleftrightarrow H-bond strength


1. Cyclic amides and ethers are stronger acceptors than acyclic ones
2. Electron-donating substituents in aromatic rings increase acceptor strength
3. Aromatic ether are weaker acceptor than aliphatic.
4. Sulfones and sulfonamides are weak H-bond acceptors and they can be found more often in hydrophobic environment or form weak H-bonds with C-H.




PDB: 2FRA

Cooperativity of H-bonds

21




antiparallel β -sheet




parallel β -sheet

Weak H-bonds


22



2.2 kcal/mol
(in gas)



1.5 kcal/mol
(in gas)




2C3L (**orange**): $K_i = 8.5 \mu\text{M}$

2C3K (**green**): $K_i = 0.026 \mu\text{M}$


Weak H-bonds

23



acceptor



donor




rare




frequent

Thrombin inhibitors




$K_i = 1.6 \mu\text{M}$




$K_i = 0.26 \mu\text{M}$


Distance preference



Ph-F




Ph-Cl, Ph-Br, Ph-I




Halogen bonding

27



PDB: 1T4E





R	Kd (μM)
-H	7.69
-I	0.067
-Br	0.83
-CCH	0.25

Halogen bond \longleftrightarrow Weak H-bond

Orthogonal multipolar interactions

28


side-on carbon interaction
above plane




antiparallel β -sheet

Orthogonal multipolar interactions


29




PDB: 3CS9




PDB: 2FL6



ATPase IC₅₀ > 50 μM



ATPase IC₅₀ = 94 nM




PDB: 1AU9




Orthogonal multipolar interactions

31


side-on carbon interaction
above plane



Angle C-X...O (°)




CSD statistics



Typical “good” environment for halogen

33



Hydrophobic effect $30 \text{ cal}/(\text{mol} \times \text{\AA}^2)$


for CH_3 0.7 kcal/mol (3.5-fold increase in affinity)

1. Desolvation and cooperative effects
2. Optimal filling of the hydrophobic pocket is $\sim 55\%$.
Residual flexibility is important!

Hydrophobic interactions


35

Example of optimal filling of hydrophobic pocket




PDB: 3KWJ


Human serine protease DPP-IV inhibitors



R	K_d (nM)
H	200
CH ₃	4.6
CH ₂ F	0.5



T-shaped



Parallel-dispaced

more often in proteins

$$E_{\text{calc}} = -2.5 \text{ kcal/mol}$$


$$E_{\text{exp}} = -1.6 \dots -2.4 \text{ kcal/mol}$$

Aryl-aryl and aryl-alkyl interactions


37

Stacking



Quadrupole moments





Benzene




Hexafluorobenzene




PDB statistics




p38 MAP kinase inhibitors




PDB: 2W26



$IC_{50} = 220 \text{ nM}$




$IC_{50} = 1.1 \text{ nM}$




PDB: 2W26

Factor Xa inhibitors






$IC_{50} = 43 \text{ nM}$



$IC_{50} = 0.7 \text{ nM}$


Cation – π interactions

41



Cation – π interactions


42




PDB: 2BOC

Factor Xa inhibitors


9800 nM




911 nM





58 nM



9 nM



550 nM



1. Improving ligand-protein interactions over those with the solvent in order to obtain a favorable (negative) change in enthalpy.
2. Making the ligand more hydrophobic in order to make the solvation entropy large and positive.
3. Pre-shaping the ligand to the geometry of the binding site in order to minimize the loss of conformational entropy upon binding.

Caterina Bissantz, Bernd Kuhn, and Martin Stahl
A Medicinal Chemist's Guide to Molecular Interactions
Journal of Medicinal Chemistry, 2010, Vol. 53, 5061-5084

Rainer Wilcken, Markus O. Zimmermann, Andreas Lange,
Andreas C. Joerger and Frank M. Boeckler
Principles and Applications of Halogen Bonding in Medicinal
Chemistry and Chemical Biology
Journal of Medicinal Chemistry, 2013, Vol. 56, 1363–1388